These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26380458)

  • 1. [Tuberculosis among patients in Israel with anti-TNF].
    Ahmed A; Guber A; Shitrit D
    Harefuah; 2015 Jul; 154(7):419-22, 470. PubMed ID: 26380458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.
    Tomio J; Yamana H; Matsui H; Yamashita H; Yoshiyama T; Yasunaga H
    Int J Rheum Dis; 2017 Nov; 20(11):1674-1683. PubMed ID: 29076252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.
    Lee EH; Kang YA; Leem AY; Park MS; Kim YS; Kim SK; Chang J; Kim SY
    Sci Rep; 2017 Jul; 7(1):6473. PubMed ID: 28743918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can ELISpot replace the tuberculin skin test for latent tuberculosis?
    Greveson K
    Br J Nurs; 2009 Nov 12-25; 18(20):1248-54. PubMed ID: 20081663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Balbir-Gurman A; Lidgi M; Elkayam O
    Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
    Martyn-Simmons CL; Mee JB; Kirkham BW; Groves RW; Milburn HJ
    Br J Dermatol; 2013 May; 168(5):1012-8. PubMed ID: 23278714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
    Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Kumar P; Vuyyuru SK; Kante B; Sahu P; Goyal S; Madhu D; Jain S; Ranjan MK; Mundhra S; Golla R; Singh M; Virmani S; Gupta A; Yadav N; Kalaivani M; Sharma R; Das P; Makharia G; Kedia S; Ahuja V
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1431-1440. PubMed ID: 35229906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test.
    Laffitte E; Janssens JP; Roux-Lombard P; Thielen AM; Barde C; Marazza G; Panizzon RG; Saurat JH
    Br J Dermatol; 2009 Oct; 161(4):797-800. PubMed ID: 19659473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.
    Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Angelberger S; Novacek G; Mikulits A; Vogelsang H; Reinisch W
    Eur J Clin Invest; 2011 Oct; 41(10):1071-6. PubMed ID: 21413978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.